Small intestinal metabolism of the 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor lovastatin and comparison with pravastatin.

We compared the intestinal metabolism of the structurally related 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors lovastatin and pravastatin in vitro. Human small intestinal microsomes metabolized lovastatin to its major metabolites 6'beta-hydroxy (apparent K(m) = 11.2 +/- 3.3 microM) and 6'-exomethylene (apparent K(m) = 22.7 +/- 9.0 microM) lovastatin. The apparent K(m) values were similar for lovastatin metabolism by human liver microsomes. 6'beta-Hydroxylovastatin formation by pig small intestinal microsomes was inhibited with the following inhibition K(i) values: cyclosporine, 3.3 +/- 1.2 microM; ketoconazole, 0.4 +/- 0.1 microM; and troleandomycin, 0.8 +/- 0.9 microM. K(i) values for 6'-exomethylene lovastatin were similar. Incubation of pravastatin with human small intestinal microsomes resulted in the generation of 3'alpha,5'beta, 6'beta-trihydroxypravastatin (apparent K(m) = 4560 +/- 1410 microM) and hydroxypravastatin (apparent K(m) = 5290 +/- 1740 microM). In addition, as in the liver, pravastatin was metabolized in the small intestine by sulfation and subsequent degradation to its main metabolite 3'alpha-iso-pravastatin. It was concluded that lovastatin is metabolized by cytochrome P-450 3A enzymes in the small intestine. Compared with lovastatin, the cytochrome P-450-dependent intestinal intrinsic clearance of pravastatin was >5000-fold lower and cannot be expected to significantly affect its oral bioavailability or to be a significant site of drug interactions.

[1]  M Rowland,et al.  Differentiation of absorption and first‐pass gut and hepatic metabolism in humans: Studies with cyclosporine , 1995, Clinical pharmacology and therapeutics.

[2]  G J Boerma,et al.  Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels. The Regression Growth Evaluation Statin Study (REGRESS). , 1995, Circulation.

[3]  H. Yeger,et al.  HMG–CoA reductase mediates the biological effects of retinoic acid on human neuroblastoma cells: Lovastatin specifically targets P–glycoprotein–expressing cells , 1996, Nature Medicine.

[4]  U. Christians,et al.  Drug interactions and interindividual variability of ciclosporin metabolism in the small intestine. , 1996, Pharmacology.

[5]  D. Greenblatt,et al.  Hepatic vs. gastrointestinal presystemic extraction of oral midazolam and flurazepam. , 1987, The Journal of pharmacology and experimental therapeutics.

[6]  M. A. Moseley,et al.  CYP3A-like cytochrome P450-mediated metabolism and polarized efflux of cyclosporin A in Caco-2 cells. , 1996, Drug metabolism and disposition: the biological fate of chemicals.

[7]  C. K. Pearson,et al.  Poly(adenosine diphosphate ribose) synthetase activity in nuclei of dividing and of non-dividing but differentiating intestinal epithelial cells. , 1979, The Biochemical journal.

[8]  R. Gregg,et al.  HMG CoA reductase inhibitor-induced myotoxicity: pravastatin and lovastatin inhibit the geranylgeranylation of low-molecular-weight proteins in neonatal rat muscle cell culture. , 1997, Toxicology and applied pharmacology.

[9]  A. Y. Lu,et al.  Biotransformation of lovastatin. IV. Identification of cytochrome P450 3A proteins as the major enzymes responsible for the oxidative metabolism of lovastatin in rat and human liver microsomes. , 1991, Archives of biochemistry and biophysics.

[10]  H. Pan,et al.  Gastrointestinal Absorption of Pravastatin in Healthy Subjects , 1995, Journal of clinical pharmacology.

[11]  U. Christians,et al.  Accumulation of lovastatin, but not pravastatin, in the blood of cyclosporine‐treated kidney graft patients after multiple doses , 1997, Clinical pharmacology and therapeutics.

[12]  S. Grundy,et al.  Rhabdomyolysis in patients receiving lovastatin after cardiac transplantation. , 1988, The New England journal of medicine.

[13]  R. Obach,et al.  Nonspecific binding to microsomes: impact on scale-up of in vitro intrinsic clearance to hepatic clearance as assessed through examination of warfarin, imipramine, and propranolol. , 1997, Drug metabolism and disposition: the biological fate of chemicals.

[14]  L. Pinkus.  [18] Separation and use of enterocytes , 1981 .

[15]  U. Christians,et al.  Comparison of cytochrome P-450-dependent metabolism and drug interactions of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors lovastatin and pravastatin in the liver. , 1999, Drug metabolism and disposition: the biological fate of chemicals.

[16]  S. Singhvi,et al.  Biotransformation of pravastatin sodium in humans. , 1991, Drug metabolism and disposition: the biological fate of chemicals.

[17]  P. Neuvonen,et al.  Itraconazole drastically increases plasma concentrations of lovastatin and lovastatin acid , 1996, Clinical pharmacology and therapeutics.

[18]  M-heart investigators.  Effect of simvastatin on coronary atheroma: the Multicentre Anti-Atheroma Study (MAAS) , 1994, The Lancet.

[19]  A. Y. Lu,et al.  Biotransformation of lovastatin--III. Effect of cimetidine and famotidine on in vitro metabolism of lovastatin by rat and human liver microsomes. , 1990, Biochemical pharmacology.

[20]  Leslie Z. Benet,et al.  Intestinal drug metabolism and antitransport processes : A potential paradigm shift in oral drug delivery , 1996 .

[21]  T. Omura,et al.  THE CARBON MONOXIDE-BINDING PIGMENT OF LIVER MICROSOMES. I. EVIDENCE FOR ITS HEMOPROTEIN NATURE. , 1964, The Journal of biological chemistry.

[22]  Sarah A. Spinier,et al.  Comparative Evaluation of the Safety and Efficacy of HMG-CoA Reductase Inhibitor Monotherapy in the Treatment of Primary Hypercholesterolemia , 1995, The Annals of pharmacotherapy.

[23]  D. Fleming,et al.  More on rifampin prophylaxis against Haemophilus influenzae b in day-care facilities. , 1988, The New England journal of medicine.

[24]  U. Christians,et al.  Metabolism of the immunosuppressant tacrolimus in the small intestine: cytochrome P450, drug interactions, and interindividual variability. , 1995, Drug metabolism and disposition: the biological fate of chemicals.

[25]  R. Heel,et al.  Lovastatin , 2012, Drugs.

[26]  P. K. Smith,et al.  Measurement of protein using bicinchoninic acid. , 1985, Analytical biochemistry.

[27]  H. Iwabuchi,et al.  Biotransformation of pravastatin sodium (I). Mechanisms of enzymic transformation and epimerization of an allylic hydroxy group of pravastatin sodium. , 1993, Biochemical and biophysical research communications.

[28]  F. Guengerich,et al.  Human cytochrome P-450 enzymes. , 1992, Life sciences.

[29]  J. Quion,et al.  Clinical Pharmacokinetics of Pravastatin , 1994, Clinical pharmacokinetics.

[30]  C. Shear,et al.  Expanded Clinical Evaluation of Lovastatin (EXCEL) study results: two-year efficacy and safety follow-up. , 1994, The American journal of cardiology.

[31]  W. F. Hoffman,et al.  Biotransformation of lovastatin. I. Structure elucidation of in vitro and in vivo metabolites in the rat and mouse. , 1990, Drug metabolism and disposition: the biological fate of chemicals.

[32]  B. Hirst,et al.  Intestinal secretion of drugs. The role of P-glycoprotein and related drug efflux systems in limiting oral drug absorption , 1997 .

[33]  D. E. Duggan,et al.  Biotransformation of lovastatin. II. In vitro metabolism by rat and mouse liver microsomes and involvement of cytochrome P-450 in dehydrogenation of lovastatin. , 1990, Drug metabolism and disposition: the biological fate of chemicals.

[34]  D. Shen,et al.  Characterization of interintestinal and intraintestinal variations in human CYP3A-dependent metabolism. , 1997, The Journal of pharmacology and experimental therapeutics.

[35]  R. Estabrook,et al.  The measurement of difference spectra: application to the cytochromes of microsomes. , 1978, Methods in enzymology.

[36]  M. Crawford,et al.  Continuous infusion of lidocaine in patients with cardiac arrhythmias. Unpredictability of plasma concentrations. , 1981 .

[37]  J. L. Smith,et al.  Metabolism of lovastatin by rat and human liver microsomes in vitro. , 1988, Drug metabolism and disposition: the biological fate of chemicals.

[38]  J. Kolars,et al.  CYP3A gene expression in human gut epithelium. , 1994, Pharmacogenetics.

[39]  S D Hall,et al.  Regioselective biotransformation of midazolam by members of the human cytochrome P450 3A (CYP3A) subfamily. , 1994, Biochemical pharmacology.

[40]  Morton B. Brown,et al.  Role of intestinal P‐glycoprotein (mdr1) in interpatient variation in the oral bioavailability of cyclosporine , 1997, Clinical pharmacology and therapeutics.